World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
71949
World Ranking
8398
National Ranking
4342

Steven I. Sherman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Steven I. Sherman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 306 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Steven I. Sherman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Steven I. Sherman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Steven I. Sherman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with notable contributions in the fields of endocrinology, diabetes and metabolism, oncology, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and genetics.

The scientist's work covers several main topics, including:

  • Thyroid Cancer Diagnosis and Treatment
  • BRCA gene mutations in cancer
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer-related Molecular Pathways
  • Cancer Genomics and Diagnostics
  • Cancer Diagnosis and Treatment

Steven I. Sherman has contributed research to frequent publication venues such as:

  • Journal of Clinical Oncology
  • Journal of the Endocrine Society
  • Thyroid
  • Annals of Oncology
  • The Journal of Clinical Endocrinology & Metabolism

Among the recent papers linked to their work are:

  • Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial (2021), The Lancet Oncology
  • Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer (2021), Journal of Clinical Oncology
  • Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape (2020), The Journal of Clinical Endocrinology & Metabolism
  • Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies (2020), ESMO Open
  • Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial (2022), Cancer

The scientist has collaborated frequently with several co-authors, including Maria E. Cabanillas, Mimi I. Hu, Ramona Dadu, Naifa L. Busaidy, and Mark Zafereo, reflecting a network of ongoing research partnerships in related medical disciplines.

Best Publications

  • 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

    Bryan R. Haugen;Erik K. Alexander;Keith C. Bible;Gerard M. Doherty

  • Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

    David S. Cooper;Gerard M. Doherty;Bryan R. Haugen;Richard T. Kloos

  • Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

    David S. Cooper;Gerard M. Doherty;Bryan R. Haugen;Richard T. Kloos

  • Integrated Genomic Characterization of Papillary Thyroid Carcinoma

    Nishant Agrawal;Rehan Akbani;B. Arman Aksoy;Adrian Ally

  • Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement

    Mary C. Frates;Carol B. Benson;J. William Charboneau;Edmund S. Cibas

  • Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

    Martin Schlumberger;Makoto Tahara;Lori J. Wirth;Bruce Robinson

  • Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

    Marcia S Brose;Christopher M Nutting;Barbara Jarzab;Rossella Elisei

  • Cabozantinib in Progressive Medullary Thyroid Cancer

    Rossella Elisei;Martin J. Schlumberger;Stefan P. Müller;Patrick Schöffski

  • A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

    Ernest L. Mazzaferri;R. J. Robbins;C. A. Spencer;L. E. Braverman

  • Outcomes of patients with differentiated thyroid carcinoma following initial therapy.

    Jacqueline Jonklaas;Nicholas J. Sarlis;Nicholas J. Sarlis;Danielle Litofsky;Kenneth B. Ain

  • A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

    Bryan R. Haugen;Furio Pacini;Christoph Reiners;Martin Schlumberger

  • Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer

    Maria A Kouvaraki;Suzanne E Shapiro;Bruno D Fornage;Beth S Edeiken-Monro

  • Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

    F Pacini;F Pacini;Pw Ladenson;M Schlumberger;A Driedger

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • Motesanib diphosphate in progressive differentiated thyroid cancer.

    Steven I. Sherman;Lori J. Wirth;Jean Pierre Droz;Michael Hofmann

  • Prospective multicenter study of thyroid carcinoma treatment initial analysis of staging and outcome

    Steven I. Sherman;D M B James Brierley;Matthew Sperling;Kenneth B. Ain

  • Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry

    David S. Cooper;Bonny Specker;Mona Ho;Matthew Sperling

  • Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal

    Heribert Hänscheid;Michael Lassmann;Markus Luster;Stephen R. Thomas

  • Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer

    Martin J. Schlumberger;Rossella Elisei;Lars Bastholt;Lori J. Wirth

  • Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

    Daniel J. Drucker;Steven I. Sherman;Fred S. Gorelick;Richard M. Bergenstal

Frequent Co-Authors

Martin Schlumberger
Martin Schlumberger University of Paris-Saclay
Robert F. Gagel
Robert F. Gagel The University of Texas MD Anderson Cancer Center
Rossella Elisei
Rossella Elisei University of Pisa
Douglas B. Evans
Douglas B. Evans Medical College of Wisconsin
Bruce G. Robinson
Bruce G. Robinson University of Sydney
Furio Pacini
Furio Pacini University of Siena
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Gilbert J. Cote
Gilbert J. Cote The University of Texas MD Anderson Cancer Center
Gary L. Clayman
Gary L. Clayman The University of Texas MD Anderson Cancer Center
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't always start—and end—with a traditional MD. Many students and professionals explore online degrees that can open doors to a wide range of roles within healthcare. For those interested in healthcare leadership, a cahme accredited online mha programs list highlights top options to earn a Master of Healthcare Administration recognized for its quality and flexibility.

Nursing professionals looking to advance their careers might consider programs designed for working adults. There are convenient online rn to bsn programs without clinicals, which allow you to complete your degree fully online – perfect if you’re balancing a job or family commitments.

For advanced practice nurses seeking the highest level of training, you can find options like a 1 year dnp program online for a fast-track Doctor of Nursing Practice. Additionally, if affordability is a concern, several affordable dnp programs are available to help reduce financial stress while achieving your career goals.

Best Scientists Citing Steven I. Sherman

Trending Scientists

Recently Published Articles